Super-resolution fluorescence microscopy instrumentation developer Bioaxial (Paris, France) has completed a $2.7 million equity investment by three large investors: Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative, and Viveris Management, plus a range of individual investors.
The investment will back the commercial launch of the company's first super-resolution fluorescence microscopy module, which will enable extended imaging of live cells with an improved resolution so far unreachable in research laboratories. The module not only allows observation of living cells in super-resolution over time without damaging them, it also does not require complex manipulations.
The module has been tested at the Institut Pasteur in Paris for the last 12 months, and it is slated for debut in the second half of 2014.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!